Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
View Patent ↗Antagonists of α4 integrin/α4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their α4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
1. A method for treating multiple myeloma in a subject comprising administering to the subject a combination of an anti-VLA-4 antibody, or antigen-binding fragment thereof, and a chemotherapeutic agent, wherein said combination is therapeutically effective to treat multiple myeloma in the subject.
2. The method of claim 1 , wherein the combination comprises a therapeutically effective amount of a first composition comprising the anti-VLA-4 antibody, or antigen-binding fragment thereof, and a therapeutically effective amount of a second composition comprising the chemotherapeutic agent.
3. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, and thalidomide.
4. The method of claim 3 , wherein the chemotherapeutic agent is melphalan.
5. The method of claim 3 , wherein the bisphosphonate is selected from the group consisting of ibandronate and pamidronate.
6. The method of claim 1 , 2 , 3 , 4 or 5 , wherein the antibody, or antigen-binding fragment thereof, is a monoclonal antibody, or antigen-binding fragment thereof.
7. The method of claim 2 , 3 , 4 or 5 , wherein the anti-VLA-4 antibody, or antigen-binding fragment thereof, is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody, and an antigen-binding Fab, Fab′, F(ab′) 2 or F(v) fragment of a human, chimeric or humanized antibody.
8. The method of claim 2 , wherein said first composition is administered at a dosage that is lower when administered in combination with said second composition than when not administered in combination with said second composition.
9. The method of claim 2 , wherein said second composition is administered at a dosage that is lower when administered in combination with said first composition than when not administered in combination with said first composition.
10. The method of claim 2 , wherein said first composition is administered at a dosage that is lower when administered in combination with said second composition than when not administered in combination with said second composition; and wherein said second composition is administered at a dosage that is lower when administered in combination with said first composition than when not administered in combination with said first composition.
11. The method of claim 1 , 2 , 3 , 4 or 5 , wherein the anti-VLA-4 antibody, or antigen binding fragment thereof, binds the α chain of VLA-4.
12. The method of claim 1 , 2 , 3 , 4 or 5 , wherein the anti-VLA-4 antibody, or antigen-binding fragment thereof, is a B epitope specific anti-VLA-4 antibody, or antigen-binding fragment thereof.
13. The method of claim 1 , 2 , 3 , 4 or 5 , wherein the anti-VLA-4 antibody, or antigen binding fragment thereof, is a humanized anti-VLA-4 antibody, or antigen-binding fragment thereof.
14. A method for treating multiple myeloma in a subject comprising administering to the subject a combination of:
(i) a humanized anti-VLA-4 antibody, or antigen-binding fragment thereof; and
(ii) melphalan,
wherein said combination is therapeutically effective to treat multiple myeloma in the subject.
15. A method for treating multiple myeloma in a subject comprising administering to the subject a combination of:
(i) an anti-VLA-4 antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is a B epitope specific anti-VLA-4 antibody, or antigen-binding fragment thereof; and
(ii) melphalan,
wherein said combination is therapeutically effective to treat multiple myeloma in the subject.
16. The method of claim 14 , wherein the humanized anti-VLA-4 antibody, or antigen-binding fragment thereof, is a B epitope specific anti-VLA-4 antibody, or antigen-binding fragment thereof.